Stock Screener App

무료 -

설치하다

23.92

0.17% 0.04

after-market

시간 외 거래: 23.92

Catalyst Pharmaceuticals Inc (CPRX)

개요 뉴스 가격 이력 옵션 체인 Financials CPRX 왜 하락? 토론 예측

Catalyst Pharmaceuticals Inc 주식(CPRX)의 최신 뉴스

Catalyst Pharmaceuticals, Inc. $CPRX Shares Sold by Vanguard Group Inc. - MarketBeat

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat

Catalyst Pharmaceuticals, Inc. $CPRX Shares Bought by Royce & Associates LP - MarketBeat

Catalyst Pharmaceuticals (CPRX) Reports Record Q4 and Full Year 2025 Results - Insider Monkey

CPRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch

Catalyst Pharmaceuticals Inc (CPRX) Q4 2025 Earnings Call Highli - GuruFocus

Catalyst Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat

Catalyst Pharmaceuticals Q4 Earnings Beat, Firdapse Revenues Rise Y/Y - Finviz

Earnings call transcript: Catalyst Pharmaceuticals Q4 2025 earnings beat expectations By Investing.com - Investing.com South Africa

Earnings call transcript: Catalyst Pharmaceuticals Q4 2025 earnings beat expectations - Investing.com India

Catalyst Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance

Catalyst Pharma Q4 Net Income Slips; Announces FY26 Outlook - Nasdaq

Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) Shows Technical Setup for Potential Breakout - ChartMill

Catalyst Pharmaceuticals (CPRX) Net Margin Strength Reinforces Bullish Earnings Narrative - Sahm

Decoding Catalyst Pharmaceuticals Inc (CPRX): A Strategic SWOT I - GuruFocus

Catalyst Pharmaceuticals (NASDAQ:CPRX) Releases Quarterly Earnings Results, Beats Expectations By $0.26 EPS - MarketBeat

Catalyst Pharmaceuticals Q4 Non-GAAP Earnings Fall, Revenue Rises - marketscreener.com

Catalyst Pharma Posts Record 2025 Results, Raises 2026 Outlook - TipRanks

Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Earnings Flash (CPRX) Catalyst Pharmaceuticals Posts Q4 Revenue $152.6M, vs. FactSet Est of $142.7M - marketscreener.com

Earnings Flash (CPRX) Catalyst Pharmaceuticals Posts Q4 Adjusted EPS $0.68, vs. FactSet Est of $0.59 - marketscreener.com

CPRX | Catalyst Pharmaceutical Inc. FinancialsIncome Statement - Quiver Quantitative

Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance - The Manila Times

Catalyst Pharmaceuticals Reports Record Fourth Quarter and - GlobeNewswire

Catalyst Pharmaceuticals earnings on deck amid growth questions - Investing.com Nigeria

Catalyst Pharmaceuticals earnings on deck amid growth questions By Investing.com - Investing.com Canada

Catalyst: Q4 Financial Results Overview - Bitget

Catalyst Pharmaceuticals, Inc. (CPRX): Strong Buy Ratings and 43% Potential Upside Propel Investor Interest - DirectorsTalk Interviews

Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Momentum Stock - Yahoo Finance

Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference - The Manila Times

Aug Volume: Is Catalyst Pharmaceuticals Inc a defensive stockAnalyst Upgrade & Verified Chart Pattern Signals - baoquankhu1.vn

Empirical Financial Services LLC d.b.a. Empirical Wealth Management Takes Position in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat

Jupiter Asset Management Ltd. Sells 116,575 Shares of Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat

CEO Change: Is Catalyst Pharmaceuticals Inc a top pick in the sectorQuarterly Market Review & Safe Capital Preservation Plans - baoquankhu1.vn

Catalyst Pharmaceuticals, Inc. $CPRX Shares Sold by Skandinaviska Enskilda Banken AB publ - MarketBeat

Aberdeen Group plc Has $12.46 Million Stake in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat

Catalyst Pharma (CPRX) HR chief receives stock from RSU vesting - Stock Titan

Catalyst Pharmaceuticals: Clear Path Forward For Growth In 2 FDA-Approved Drugs (CPRX) - Seeking Alpha

BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy? - Finviz

Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock - Yahoo Finance

Analysts Estimate Catalyst Pharmaceutical (CPRX) to Report a Decline in Earnings: What to Look Out for - Finviz

Catalyst Pharmaceuticals (CPRX) Expected to Announce Earnings on Wednesday - MarketBeat

Catalyst Pharmaceuticals (CPRX) Stock Analysis: 42% Upside Potential Ignites Investor Interest - DirectorsTalk Interviews

Public Sector Pension Investment Board Grows Stock Holdings in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat

Aug Retail: Is Catalyst Pharmaceuticals Inc a momentum stock2025 Retail Activity & Weekly Watchlist for Hot Stocks - baoquankhu1.vn

Is Catalyst Pharmaceuticals Inc.’s growth already priced inTrade Exit Summary & Fast Gain Stock Trading Tips - mfd.ru

Is Catalyst Pharmaceuticals Inc. stock attractive for hedge fundsJuly 2025 Analyst Calls & Stepwise Entry and Exit Trade Signals - mfd.ru

What is Catalyst Pharmaceuticals Inc. s 5 year growth outlookQuarterly Profit Report & Weekly Setup with High ROI Potential - mfd.ru

Will Catalyst Pharmaceuticals Inc. benefit from government policy2025 Sector Review & High Accuracy Swing Entry Alerts - mfd.ru

Block Trades: Is iShares Gold Trust impacted by rising ratesInflation Watch & Community Consensus Trade Alerts - baoquankhu1.vn

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 - GlobeNewswire

Catalyst Pharmaceuticals (CPRX) Investor Outlook: A Promising 41.4% Upside Potential - DirectorsTalk Interviews

Rare-disease drugmaker Catalyst sets Feb. 26 call on 2025 results - Stock Titan

Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Renewed Interest And Pocket Pivot Signal - Sahm

Allianz Asset Management GmbH Cuts Stake in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Combines Strong Growth with Bullish Technical Setup - ChartMill

Catalyst Pharmaceuticals (NASDAQ:CPRX) shareholders have earned a 41% CAGR over the last five years - Yahoo Finance

What is the next catalyst for Oramed Pharmaceuticals Inc.July 2025 Sentiment & Stock Portfolio Risk Control - Mfd.ru

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat

Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term - Yahoo Finance

Catalyst Pharmaceuticals, Inc. $CPRX Shares Acquired by Federated Hermes Inc. - MarketBeat

MRNA

$49.83

5.71%

ROIV

$27.85

0.89%

RPRX

$47.48

0.02%

BNTX

$100.76

6.25%

INSM

$147.00

0.46%

ONC

$297.04

5.51%

야후에서 열기 | 구글에서 열기 | 핀비즈에서 열기 | MarketWatch에서 열기 | EDGAR에서 열기 | 로이터에서 공개